The IAA One Minute Blog

Pfizer announced on March 23, it has begun a U.S. based early-stage study of an oral anti-viral drug to treat COVID-19.

Oral COVID-19 Treatment

The Phase 1 trial involves healthy adults to evaluate safety and tolerability of the drug.

The antiviral candidate is called PF-07321332. It is a protease inhibitor and could be prescribed to patients showing the first signs of a COVID-19 infection.

Protease inhibitors work by binding to a viral enzyme, preventing a virus from replicating inside a cell.

PF-07321332 was designed as a potential oral therapy that could be prescribed at the first sign of infection, without requiring that patients are hospitalized or in critical care.

Fighting COVID-19

Currently, the best available method to fight the coronavirus is through vaccination. Three vaccines are now authorized and recommended to protect against COVID-19:

1. Pfizer-BioNtech: This requires two shots given 21 days apart.
2. Moderna: This requires two shots given 28 days apart.
3. Johnson & Johnson/Janssen: This only requires one shot.

COVID-19 vaccines help our bodies develop immunity to the virus that causes coronavirus without people having to get the illness.

What IAA has to Say

Insurance Administrator of America wants to keep you up-to-date on the world of health. Stay tuned to this blog to learn more. Remember, with IAA one call does it all.

Interested in reading more on this topic? Click here.